Navigation Links
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/28/2013

CHAPEL HILL, N.C., Feb. 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2012. The company will host a conference call and webcast at 4:30 p.m. EST, today.

"2012 was a transformational year for Cempra," said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra. "We raised sufficient capital through our IPO and a subsequent private placement to advance our two differentiated antibiotics in clinical development.  Solithromycin is now in the first of two planned Phase 3 clinical trials in community-acquired bacterial pneumonia or CABP and Taksta (CEM-102) is undergoing a Phase 2 trial in patients with prosthetic joint infections or PJIs.  2013 will also be an important year as we expect to hold an end-of-Phase 2 meeting with the FDA during the first half of 2013 for solithromycin in CABP as the key step in preparing for the IV-to-oral second Phase 3 trial, which we expect to start in the second half of 2013 subject to available resources.  We also anticipate presenting some top-line results for the TAKSTA™ Phase 2 trial in PJIs in the fourth quarter of 2013."

Financial ResultsQuarter ended December 31, 2012 compared to quarter ended December 31, 2011

For the quarter ended December 31, 2012, Cempra reported a net loss of $6.6 million, or $0.26 per share, compared to a net loss of $3.8 million, or $7.13 per share, for the same period in 2011. 

Research and development expense in the quarter ended December 31, 2012, was $4.4 million, a 20
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Patent and Trademark Office to Require Signed NDA Affects Many Reports Wysebridge
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
3. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
4. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
11. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... at USD 161,056.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... is witnessing a significant growth due to the increasing ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced financial results for the ... 2014 Financial Summary: , Reported cash and cash ... with $137,000 at December 31, 2013.  , Reported ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... BEIJING , May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: ... Shengmingsu brand plant and animal nutrient products in the,People,s Republic of ... four investment conferences in May 2010 . , ... The date, time and ...
... BEIJING , May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: ... distributor of Shengmingsu brand plant and animal nutrient products in ... has started,the construction of a new production facility in Wuchuan County, ... , , ...
... ... LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons directory service and website ... seeking to improve their vision and find a highly qualified eye surgeon ... sets the Trusted LASIK Surgeons directory apart is a unique screening process ...
Cached Biology Technology:Yongye International to Present at Upcoming Investor Conferences 2Yongye International to Present at Upcoming Investor Conferences 3Yongye International, Inc. Begins Construction of New Production Facility 2Yongye International, Inc. Begins Construction of New Production Facility 3Yongye International, Inc. Begins Construction of New Production Facility 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 2Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 3Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 5Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 6Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 7Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 8Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 9
(Date:7/27/2014)... RESEARCH UK scientists at Barts Cancer Institute have found ... cancer therapy significantly more effective, according to research published ... Barts Cancer Institute, part of Queen Mary University of ... kinase (FAK), signals the body to repair itself after ... DNA. When the researchers removed FAK from blood vessels ...
(Date:7/25/2014)... 25, 2014 In the first broad-scale estimate of air ... and collaborators calculated that trees are saving more than ... of acute respiratory symptoms. , While trees, pollution removal ... than 1 percent, the impacts of that improvement are ... reduced air pollution at nearly $7 billion every year ...
(Date:7/25/2014)... been raging this summer and some of the smoke from ... this image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) ... of smoke has descended over the Great Lakes region of ... fire image from July 23, 2014 (first image feature highlighted ... drifts off southeastward. In the image, it is over ...
Breaking Biology News(10 mins):New drug target can break down cancer's barrier against treatment 2First national study finds trees saving lives, reducing respiratory problems 2
... Sheng Yang He, plant biologist at Michigan State ... plant scientists as part of a $75 million new ... Institute and the Gordon and Betty Moore Foundation honored ... and 14 other researchers from around the country. The ...
... Spring Harbor, N.Y. The Howard Hughes Medical Institute (HHMI) ... selected Professor Rob Martienssen, Ph.D., of Cold Spring Harbor ... basic research in fundamental plant science. Dr. Martienssen is ... scientists who have been named HHMI-GBMF Investigators in plant ...
... Md. (June 16, 2011) Coaches, physiologists and athletes ... before athletic competition. Warming up increases muscle temperature, accelerates ... which enhance performance. However, the question of how long ... with some in the sports community advocating longer warm-ups ...
Cached Biology News:MSU plant scientist named one of the nation's most innovative researchers 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 3CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 4When warming up for the cycling race, less is more 2When warming up for the cycling race, less is more 3
Request Info...
IHC Detection Kit (Broad Spectrum AEC)....
... Dissociation Buffers are membrane-filtered isotonic and ... agents and cell-conditioning agents in either ... solution or Ca2+- and Mg2+-free ... mammalian cells from support substrates and ...
Request Info...
Biology Products: